← Back to overview

BIIB Biogen Inc.

Biotechnology · $202.19 +0.78%
EN PL
Price Alert:

Compare

Shows % change over the period so different-priced stocks can be compared fairly.

Technical Indicators

RSI (14)
49.2
Relative Strength Index (RSI): measures how fast and how much the price has moved recently, on a 0-100 scale. Above 70 is often called "overbought" (may be due for a pause or pullback); below 30 is "oversold" (may be due for a bounce). It is not a guarantee either way.
SMA 20 / 50 / 200
205.19 / 199.37 / —
Moving Averages (SMA): the average closing price over the last N days, smoothing out day-to-day noise. When price trades above its moving averages, and shorter averages are above longer ones, it is generally read as a healthier trend.
MACD / Signal
0.18 / 1.09
MACD: compares two moving averages (12-day and 26-day) to gauge momentum. When the MACD line crosses above its signal line, momentum is turning up; crossing below suggests momentum turning down.

Fundamentals

P/E
21.7
Price-to-Earnings ratio: how many dollars investors pay for $1 of the company's annual profit. Higher usually means the market expects faster growth (or the stock is expensive); lower can mean it's cheap — or that growth is expected to slow.
Market Cap
29.85B
Market Capitalization: the total value of all the company's shares — share price × number of shares. A rough measure of company size.
Div Yield
Dividend Yield: the annual cash dividend paid to shareholders, as a percentage of the current share price.
52-Week Range
124.56 – 219.72
52-Week Range: the lowest and highest price the stock has traded at over the last year. Where the price sits in this range hints at recent strength or weakness.

Trend Analysis

Biogen Inc. is trading at $202.19, +0.78% versus the previous close. The price sits roughly in the middle of its 52-week range.
RSI is in a neutral range — no strong overbought/oversold signal.
MACD is below its signal line — momentum currently leans negative.
Combine this reading with the fundamentals below before forming a view — no single indicator is a guarantee of what happens next.

Latest News

Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales?
Zacks · 2026-07-24 14:57
Rothschild & Co Redburn Adjusts Price Target on Biogen to $210 From $190, Maintains Neutral Rating
MT Newswires · 2026-07-24 13:36
Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know
Zacks · 2026-07-23 14:00
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
Zacks · 2026-07-22 14:00
3 Profitable Stocks We Steer Clear Of
StockStory · 2026-07-21 12:46
BofA Securities Adjusts Biogen Price Target to $215 From $217
MT Newswires · 2026-07-21 12:15
Guggenheim Adjusts Price Target on Biogen to $280 From $260, Maintains Buy Rating
MT Newswires · 2026-07-21 11:05
VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform
Exec Edge · 2026-07-20 16:15
Educational information only. Nothing here is investment advice — always do your own research and consider talking to a licensed financial advisor before buying or selling.
Data: Yahoo Finance, refreshed periodically and cached locally.